Amylyx Pharmaceuticals (AMLX) Expected to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.36) per share and revenue of $0.0690 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock opened at $19.73 on Thursday. The stock has a market capitalization of $2.19 billion, a P/E ratio of -13.15 and a beta of -0.20. The company has a 50 day moving average price of $16.27 and a 200 day moving average price of $15.35. Amylyx Pharmaceuticals has a fifty-two week low of $7.48 and a fifty-two week high of $20.21.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. boosted its holdings in Amylyx Pharmaceuticals by 17.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after purchasing an additional 1,825 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $25,000. The Manufacturers Life Insurance Company raised its holdings in Amylyx Pharmaceuticals by 13.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock worth $326,000 after purchasing an additional 3,198 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Amylyx Pharmaceuticals by 1,116.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock worth $54,000 after purchasing an additional 4,088 shares in the last quarter. Finally, California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $28,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

AMLX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Guggenheim increased their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Mizuho increased their price objective on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, July 20th. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.62.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.